Role of lymphatic polychemotherapy and EHF therapy in treatment of colorectal cancer complicated by carcinomatosis of abdominal cavity

Title:

Role of lymphatic polychemotherapy and EHF therapy in treatment of colorectal cancer complicated by carcinomatosis of abdominal cavity
Role of lymphatic polychemotherapy and EHF therapy in treatment of colorectal cancer complicated by carcinomatosis of abdominal cavity

Creator:

Akbarov, E.T., Navruzov, S.N., Abdujapparov, S.B., and Islamov, H.D.

Contributor:

Akbarov, E.T., Navruzov, S.N., Abdujapparov, S.B., and Islamov, H.D.

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:bmc14045862-cd0dca67-9b08-4148-b95c-3970a3c1e062
uuid:bmc14045862-cd0dca67-9b08-4148-b95c-3970a3c1e062
local:bmc14045862
http://ojs.journals.cz/index.php/EMHPJ/issue/archive
local: bmc14045862

Subject:

kolorektální nádory--komplikace--terapie, břišní dutina--patologie, chemoradioterapie adjuvantní--metody, peritoneum--patologie, organoplatinové sloučeniny--aplikace a dávkování--terapeutické užití, pooperační péče, protokoly antitumorózní kombinované chemoterapie, kolostomie, kombinovaná terapie, výsledek terapie, and lidé

Type:

model:article, article, Text, statistics, and TEXT

Format:

braille, electronic resource, remote, and elektronický zdroj

Description:

Aim: to improve treatment results of colorectal cancer, complicated carcinomatosis of abdominal cavity, by associated using of endolymphatic chemotherapy (ELCT) and local extremely high frequency (EHF) therapy. Igroup – 21 people (33.3%) performed colostomy, then neoadjuvant systemic chemotherapy by the scheme FOLFOX4. It was held two cycles, after two cycles their were received cytoreductive surgery; II group – 26 people (41,3%) received cytoreductive operations with early postoperative intraabdominal chemotherapy by oxaliplatin (200 mg/m(2) at day 1 and 5FU 650 mg/m(2) from days 1 to 4. III group – 16 people (25,4%) also performed colostomy, then used 2 courses of ELCT with local EHF therapy and all patients were received cytoreductive operations. ELCT was carried out injecting oxaliplatin100 mg/m(2) a day during 12 hours and then 5 – FU in doze of 600 mg/m2 a day during 72 hours by the instrumentality of the dozer and LV200 mg/m(2) (2h intravenous infusion). During ELCT patients received local EHF therapy in abdominal cavity for an hour. After chemotherapy the partial regress of tumor observed in 1st group in 4,8 % and in 3rd –37,5 %, stabilization of process noted in 28,6 and 50% cases, progressing –66,7 and 12,5% cases correspondingly to groups. Histomorphologic study of malignant foci after ELCT+EHF therapy showed reduction of specific area of parenchyma cancer cell from 57 till 39% simultaneous growth of stroma from 40 till 58% and in necrosis area – from 1,8 till 2,5%. Mitotic activity of tumor cells in the 1st group decreased (average in 22 un.), but in 3rd group it decreased until 11 units. Analysis of life span showed that in 1st group of patients 2year survival rate was 66,7%. In 2nd group of patients 2year survival rate was 42,3%. ELCH+EHFtherapy has high clinic efficacy and promotes to decrease terms of progression of tumor process, increases life span from 0 till 24% and quality of life of the patients. ELCH+EHFtherapy brings to reduction of specific area of parenchyma in cancer cells from 57 till 39% with simultaneous growth of stroma area from 40 till 58% and necrosis area – from 1,8 till 2,5%. ELCT+EHFtherapy lowers mitotic activity of tumor cells, activates apoptosis, hemodynamic and metabolic rates., Akbarov E.T., Navruzov S.N., Abdujapparov S.B., Islamov H.D., and Literatura

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Relation:

European medical, health and pharmaceutical journal--MED00177703

Source:

European medical, health and pharmaceutical journal : open access reviewed journal | 2010 Volume:2010 | Number:1

Harvested from:

CDK

Metadata only:

false

Date:

2010